NIH-funded research U01 cooperative agreement

Genomic risk tools to guide chronic disease care in adults

Official title: Integrating Genomic Risk Assessment for Chronic Disease Management in a Clinical Population

Funded at University of Alabama at Birmingham · NIH-11512953 · Data updated 2026-11-12

A program uses genetic risk scores along with health history to tailor prevention and early care for adults with chronic diseases.

More Chronic Disease research and trials

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionUniversity of Alabama at Birmingham
NIH-funded
Lab location1 site (Birmingham, United States)
Project startJune 1, 2026
Project endApril 30, 2027
Funding year2026
Award (this year)$856,003
NIH project number3U01HG011167-05S2
Project IDNIH-11512953 on NIH RePORTER

Who could benefit from this research

Could help

Adults with chronic diseases who have available clinical history and can participate in genomic-informed risk assessment within their healthcare system.

Less likely to help

Patients without access to their electronic health records or who do not consent to genomic risk sharing may not benefit from the intervention.

What this research studies

This project aims to blend genomic risk data with clinical and family health history to create a genome-informed risk assessment that guides proactive care for adults with chronic conditions. It builds on prior work from the eMERGE network, applying polygenic and monogenic risk information to 11 conditions and returning risk insights plus guidance on preventive steps to patients. The University of Alabama at Birmingham leads data harmonization, analysis, and outcomes assessment across multiple sites to understand how this approach works in real-world clinical populations. Participants will be adults with chronic disease who may receive personalized risk reports and recommendations through electronic medical records integration. The study emphasizes translating genomic insights into actionable, timely interventions to slow or prevent disease progression.

Why it matters

Potential benefit: If successful, patients could receive personalized risk information that informs earlier screening and tailored prevention strategies.

How similar studies have gone: Prior work within the eMERGE network has demonstrated feasibility and informative risk reporting to patients, with ongoing evaluation of outcomes.

Where this research is happening

  • University of Alabama at Birmingham
    Birmingham, United States
    Active

Researchers

  • Principal investigator: Limdi, Nita a — University of Alabama at Birmingham
  • Study coordinator: Limdi, Nita a

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.